Cost-effectiveness of internet-delivered

- cognitive behaviour therapy for body dysmorphic disorder: results from a
- 4 randomised controlled trial

Oskar Flygare¹, Erik Andersson², Gjermund Glimsdal², David Mataix-Cols¹,

- Diana Djurfeldt¹, Christian Rück¹, Jesper Enander¹
 Author information
- 8 Corresponding author: Oskar Flygare, oskar.flygare@ki.se. M46, Karolinska University Hospital, SE-141 86 Huddinge, Sweden.
- 10 Affiliations:
 - 1 Centre for Psychiatry Research, Department of Clinical Neuroscience,
- 12 Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Sweden
- 2 Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Sweden
- 16 E-mail addresses:
 - Oskar Flygare (oskar.flygare@ki.se)
- Erik Andersson (erik.m.andersson@ki.se)
 - Gjermund Glimsdal (g.glimsdal@gmail.com)
- 20 David Mataix-Cols (david.mataix.cols@ki.se)
 - Diana Djurfeldt (diana.djurfeldt@ki.se)
- Christian Rück (christian.ruck@ki.se)
 - Jesper Enander (jesper.enander@ki.se)

24 Abstract

Objectives: To evaluate the cost-effectiveness of internet-delivered cognitive

26 behaviour therapy for body dysmorphic disorder (BDD-NET).

Design: Secondary cost-effectiveness analysis from a randomised controlled trial

28 on BDD-NET versus online supportive psychotherapy.

Setting: Academic medical centre.

- 30 **Participants:** Self-referred adult patients with a primary diagnosis of body dysmorphic disorder and a score of 20 or higher on the modified Yale-Brown
- obsessive compulsive scale (n = 94). Patients receiving concurrent psychotropic drug treatment were included if the dose had been stable for at least two months
- and remained unchanged during the trial.

Interventions: Participants received either BDD-NET (n = 47) or online

36 supportive psychotherapy (n = 47) for 12 weeks.

Primary and secondary outcome measures: The primary outcome measures

- 38 were cost-effectiveness and cost-utility from a societal perspective, using remission status from a diagnostic interview and quality-adjusted life years from
- 40 EQ-5D, respectively. Secondary outcome measures were cost-effectiveness and cost-utility from a health care perspective and the clinic's perspective.
- 42 **Results:** Compared to supportive psychotherapy, BDD-NET produced one additional remission for an average societal cost of \$4132. The cost-utility
- analysis showed that BDD-NET generated one additional QALY to an average cost of \$14319 from a societal perspective.

Conclusions: BDD-NET is a cost-effective treatment for body dysmorphic 46 disorder, compared to online supportive psychotherapy. The efficacy and cost-

48 effectiveness of BDD-NET should be directly compared to face-to-face cognitive

behaviour therapy.

50 **Trial registration:** NCT02010619

Strengths and limitations of this study

52 This is the first cost-effectiveness evaluation of a novel internet-delivered

treatment designed to increase access to cognitive behaviour therapy for

54 patients with body dysmorphic disorder

Cost estimations were self-rated and might not capture all costs associated

56 with treatment

The self-referred participants were likely motivated to undergo treatment.

Keywords: "body dysmorphic disorder, cognitive behaviour therapy, cost-58

effectiveness"

60 Word count: 2961

Background

62 Body dysmorphic disorder (BDD) is characterised by an intense pre-occupation

with perceived flaws in appearance that are not noticeable or appear slight to

64 others. Cognitive behaviour therapy (CBT) is an effective treatment for BDD (1–

4), but few patients receive this evidence-based treatment for BDD. In one online

survey, only 18% of patients with BDD had ever received CBT (5). Barriers to 66

treatment include shame and stigma associated with BDD, the costs of treatment,

and belief that a treatment would not work (5,6). In addition, there is a shortage of

specialised CBT therapists, particularly in areas far away from universities and

CBT training centres (7). Thus, specialist CBT for BDD is inaccessible for most

patients.

72 Internet-delivered cognitive behaviour therapy (ICBT) has been developed for a

range of mental health disorders in an effort to improve access to evidence-based

74 treatment (8). ICBT interventions include the same content as regular CBT and

differ only in the mode of delivery: the patient logs into a secure web-based

76 platform to access treatment content and communicate with a therapist. Previous

studies have shown that therapist-guided ICBT for BDD (BDD-NET) is an

78 efficacious treatment for adults with BDD, with effects sustained up to two years

after treatment (9-11). An advantage of remote treatments such as BDD-NET is

80 that they require less therapist time per patient, enabling more patients to access

therapy and reducing costs. However, the cost-effectiveness of BDD-NET has not

82 been formally evaluated. Here, we analysed cost data from our controlled trial (9)

and evaluated the cost-effectiveness of BDD-NET compared to online supportive

84 psychotherapy. We hypothesised that BDD-NET would be cost-effective from

societal, health care, and the clinic's perspectives.

Methods

86

Trial design

88 This study reports planned secondary cost-effectiveness analyses from a randomised controlled trial comparing BDD-NET to supportive psychotherapy (N

- 90 = 94) (9). The study was approved by the regional ethical review board in Stockholm (2013/1773-31/4) and pre-registered at clinicaltrials.gov
- 92 (NCT02010619). Recruitment, treatment, and follow-up in the original study was conducted between November 2013 and January 2015. The results are reported in
- 94 accordance with the CHEERS reporting guidelines for health economic evaluations (12).

96 Participants

Included participants had a primary diagnosis of BDD according to the Diagnostic

- and Statistical Manual of Mental Disorders, 5th edition (DSM-5; (13)), were at least 18 years old, had access to the internet, and a score of 20 or above on the
- modified Yale-Brown obsessive-compulsive scale for BDD (BDD-YBOCS; (14)).

 Participants who were taking psychotropic drugs were asked to keep their dose
- stable during the study period. Exclusion criteria were initiation or changes in
 - psychotropic drug treatment within two months before enrolment, completed CBT
- 104 for body dysmorphic disorder within the past 12 months, ongoing psychological treatment, current substance dependence, bipolar disorder or psychosis, acute
- suicidal ideation, or a severe personality disorder that could jeopardize participation in treatment (such as borderline personality disorder with self harm).

108 Interventions

BDD-NET

- BDD-NET was delivered through a secure online platform hosted at a dedicated
 - hospital server with encrypted traffic. The treatment was based on a validated
- 112 CBT protocol for body dysmorphic disorder (15), contained eight text-based

modules accompanied by worksheets and homework assignments, and lasted 12

weeks. Participants were asynchronously supported by a therapist through a built-

in email system on the BDD-NET webpage and could log in to send emails at any

time. Therapists would then review and respond to messages within 36 hours on

weekdays.

116

118 The therapists involved were four clinical psychology students with basic clinical

training but with no prior experience of treating BDD. They received weekly

supervision sessions with an experienced clinician (author JE) who also monitored

messages on the platform to ensure treatment integrity and adherence to protocol.

122 Online supportive psychotherapy

Participants receiving online supportive psychotherapy had access to the email

124 system on the BDD-NET webpage and received support in a similar way to BDD-

NET. The therapists used counselling techniques such as reflecting, empathising

and summarising in order to provide the same level of caregiver attention as

BDD-NET. Notably, the supportive therapy did not include core parts of BDD-

128 NET such as exposure with response prevention. For more detailed descriptions of

the interventions, please see the main outcome paper (9).

Measures

130

Clinical outcomes

132 The cost-effectiveness analyses were based on remission status and quality-

adjusted life years (QALYs). Remission was defined as no longer meeting

diagnostic criteria for body dysmorphic disorder in a structured interview with a

clinician, blinded to treatment allocation. QALYs were estimated based on the

- self-rated EuroQol (EQ-5D) which is divided into five health domains: mobility, self-care, pain/discomfort, daily activities, and anxiety/depression. An index
- QALY score is then calculated ranging from 0 (dead) to 1 (perfect health) (16).

Health economic measures

- We used the Trimbos questionnaire for costs associated with psychiatric illness (TIC-P) to gather information on self-rated costs in the past month (17). Costs
- were analysed from a societal perspective by including all direct and indirect, medical and non-medical costs (e.g., productivity losses, sick leave). From a
- health care perspective, costs directly associated with treatment and costs from other health care visits and medications were included. Finally, costs from the
- clinic's perspective included only the cost of providing treatment (e.g., therapist salary). Costs for medications were calculated from market prices, and health care
- visit costs were based on tariffs from official listings for the Swedish health care system (see supplemental materials). Productivity losses were based on the mean
- gross earning in Sweden in 2014 (188 SEK), and domestic work cutback was estimated using the hourly tariff of €14 (18). The TIC-P was administered at pre-
- treatment, post-treatment and follow-up. Costs were summarised in Swedish Crowns, extrapolated to 12 weeks in order to cover the full duration between
- assessments, and converted to US dollars based on purchasing power parities for the year 2014 where 6.861 SEK paid one USD.

Statistical analyses

156

All analyses were intention-to-treat with the assumption that data were missing at random. Costs from the three perspectives (societal, health care, clinic) were analysed with remission status and QALY change from pre-treatment to post-

- 160 treatment and follow-up as outcomes, respectively. Mixed-effects linear regression for repeated measures were used for outcomes and costs, with fixed
- effects of group and time, their interaction, as well as a random intercept term.

 Missing values were estimated using maximum likelihood estimation in the
- mixed-effects models, and non-parametric bootstrapping (1000 replications) was used to estimate group differences which were based on the group * time
- interaction effects. The "net benefit" approach was used by estimating the probability of cost-effectiveness under different societal willingness-to-pay
- scenarios (19). Standardised Cohen's d effect sizes were estimated for both within-group and between-group changes based on the least-squares means from
- the models, using the residual standard deviation of random effects as sigma (20).

 We used R version 4.0.2 (21) for all analyses and the analytical code is available
- on the Open Science Framework https://doi.org/10.17605/OSF.IO/DC69E.

Results

174 Completion rates and participant characteristics

A majority of the participants were female (n = 80 (85%)) and the average age of

- all the participants was 32.6 (SD = 11.97). See table 1 for demographic and baseline assessment information for both treatment groups. All 94 participants
- completed the post-treatment diagnostic interview, and at follow-up, 85 (90%) participants completed the diagnostic interview (BDD-NET: 40/47 = 85%,
- supportive therapy: 45/47 = 96%). Completion rates for EQ-5D were similar, with 92 (98%) assessments (BDD-NET: 45/47 = 96%, supportive therapy: 47/47 =
- 182 100%) at post treatment, and 80 (85%) assessments completed at follow-up

- (BDD-NET: 36/47 = 77%, supportive therapy: 44/47 = 94%). Completion rates
- for the TIC-P cost assessment were high with 91 (97%) responses at post treatment (BDD-NET: 45/47 = 96%, supportive therapy: 46/47 = 98%) and 79
- 186 (84%) responses at follow-up (BDD-NET: 36/47 = 77%, supportive therapy: 43/47 = 91%). Figure 1 shows participant flow through the different assessment
- points.

INSERT FIGURE 1 HERE

- 190 **Caption:** Figure 1. Diagram of participant flow and completion of measures.

 Abbreviations: BDD-NET, internet-delivered therapist-guided cognitive
- 192 behaviour therapy for body dysmorphic disorder; EQ-5D, EuroQol 5-Dimensions; TIC-P, Trimbos questionnaire for costs associated with psychiatric
- 194 illness.

Table 1. Sample characteristics		
	Online supportive therapy	BDD-NET
n	47	47
Female, n (%)	41 (87%)	39 (83%)
Age (mean (SD))	31.32 (10.12)	33.87 (13.55)
Education, n (%)		
Primary school	6 (13%)	4 (9%)
High school	23 (49%)	31 (66%)
College/university	17 (36%)	11 (23%)
Doctorate	1 (2%)	1 (2%)
SSRI, n (%)	8 (17%)	5 (11%)
Pre-treatment BDD- YBOCS (mean (SD))	28.51 (4.55)	29.13 (5.02)
Pre-treatment EQ-5D (mean (SD))	0.75 (0.18)	0.71 (0.22)

Clinical efficacy

- The proportion of remitters at post-treatment, i.e. participants that no longer met diagnostic criteria according to the structured interview, were 32% [95% CI 20 to
- 198 46] in the BDD-NET group and 2% [95% CI 0 to 14] in the group that received supportive therapy. Patients in the BDD-NET group were more likely to be in
- remission at post-treatment (OR = 3.07, SE = 1.06, p = .004). At follow-up,

results were similar with a higher proportion of remitters in the BDD-NET group 202 40% [95% CI 26 to 56] compared to supportive therapy 9% [95% CI 3 to 21] and corresponding difference in a direct comparison (OR = 1.92, SE = 0.62, p = .002). 204 EQ-5D QALY estimates at post-treatment were on average 0.73 [95% CI 0.66 to 0.8] in the BDD-NET group and 0.67 [95% CI 0.61 to 0.74] in the supportive 206 therapy group, with a small increase from pre-treatment in the BDD-NET group (d = 0.08 [95% CI - 0.34 to 0.5]) and a medium-sized decrease in the supportive 208 therapy group (d = -0.39 [95% CI -0.8 to 0.03]). At follow-up, the estimates were largely unchanged with an average of 0.8 [95% CI 0.72 to 0.87] in the BDD-NET 210 group and 0.67 [95% CI 0.6 to 0.74] in the group that received supportive therapy. Within-group effect sizes from pre-treatment to follow-up were d = 0.46 [95% CI 212 0 to 0.91] for BDD-NET and d = -0.41 [95% CI -0.83 to 0.01] for supportive therapy. The between-group effect sizes were small at post-treatment (d = 0.29214 [95% CI -0.22 to 0.8]) and medium at follow-up (d = 0.69 [95% CI 0.15 to 1.24]). Costs 216 Costs from the societal perspective (e.g., including all direct, indirect, medical and non-medical costs) increased in the BDD-NET group (b = \$928) and decreased in 218 the supportive therapy group (b = \$-302) groups over the course of treatment, and decreased in both groups between post-treatment and follow-up (BDD-NET: b =220 \$-386, supportive therapy: b = \$-243). Similarly, when looking at costs from a health care perspective (e.g., direct medical costs from visits and medications), 222 costs from pre- to post-treatment increased in BDD-NET (b = \$982) and were stable in supportive therapy (b = \$-55). From post-treatment to follow-up, costs 224 were stable (BDD-NET: b = \$103) or decreased slightly (supportive therapy: b =

\$-269). Detailed descriptions of costs for all sub-categories are shown in the supplemental materials.

The cost of providing treatment from the clinic's perspective included the salary

cost of therapists and was estimated to \$946 for BDD-NET and \$461 for

supportive therapy. This cost corresponds to an average time of 15.7 minutes per

patient and week for BDD-NET and 7.7 minutes for supportive therapy.

Cost-effectiveness and cost-utility

232 The societal perspective

226

treatment was investigated up until the 3-month controlled follow-up, after which the control group was offered BDD-NET. The cost-effectiveness ICER at post-

The cost-effectiveness of BDD-NET versus the supportive therapy control

treatment was 1231 / 0.3 = \$4132 per case in remission. At follow-up, the corresponding numbers were 1088 / 0.29 = \$3731 per case in remission. BDD-

NET was cost-effective from a societal perspective, given that society is willing to pay up to \$4132 per case in remission after treatment. A majority of ICERs from

240 bootstrapped samples were located in the northeast quadrant, confirming higher efficacy and costs of BDD-NET compared to online supportive therapy (Figure

242 2A).

244

Cost-utility analyses (analyses of QALYs in relation to costs) indicated that the societal cost for one additional QALY gain from BDD-NET versus supportive


therapy was 1231 / 0.09 = \$14319 at post-treatment, and 1088 / 0.16 = \$6784 at

follow-up. Given the small differences in EQ-5D QALY gain, BDD-NET achieved 75% cost-utility at a societal willingness to pay of \$29000 at post-

treatment (Figure 2C). Again, the majority of ICERs from bootstrapped samples were located in the northeast quadrant of the cost-effectiveness plane (Figure 2B).

INSERT HIGH-RESOLUTION FIGURE HERE

250



- 252 **Caption:** Figure 2. Pre-treatment to post-treatment cost-effectiveness of BDD-NET compared to supportive therapy. Cost-effectiveness planes for BDD
- 254 remission rates (2A), QALYs (2B), and acceptability curves (2C). Costs are from a societal perspective and based on the TIC-P questionnaire using Swedish health
- care tariff listings and national statistics. Abbreviations: BDD-NET, internetdelivered cognitive behaviour therapy for body dysmorphic disorder; ICER,
- 258 incremental cost-effectiveness ratio; QALYs, Quality-adjusted life years.

The health care perspective

- 260 From the health care perspective, which includes costs of health care and medications (but excludes non-medical or indirect costs), the cost-effectiveness of
- BDD-NET at post treatment was 1037 / 0.3 = \$3482 per case in remission. The cost-effectiveness of BDD-NET versus supportive therapy at follow-up was 1409
- 264 / 0.29 = \$4831. Compared to supportive therapy, BDD-NET was estimated to have an additional cost of \$3482 per case in remission, and the ICERs from

bootstrapped samples were located in the northeast quadrant of the costeffectiveness plane (see supplemental materials).

The clinic's perspective

268

274

The clinic's perspective includes the cost of delivering the interventions (in this case, the cost of the psychologists' time). The cost-effectiveness of BDD-NET compared to supportive therapy at post-treatment was 485 / 0.3 = \$1628 per case in remission. At follow-up, cost-effectiveness was 485 / 0.29 = \$1662. Again, the ICERs from bootstrapped samples were located inn the northeast quadrant of the

Discussion

14

cost-effectiveness plane.

- To our knowledge, this is the first cost-effectiveness study of a psychological treatment for BDD. We found that therapist-guided internet-delivered cognitive behaviour therapy for body dysmorphic disorder (BDD-NET) produced one additional remission for an average societal cost of \$4132 and the cost-utility analysis showed that BDD-NET generated one additional QALY to an average price of \$14319 from a societal perspective, compared to online supportive therapy. Results were similar when costs from a health care perspective and the clinic's perspective were considered.
- Previous studies on the cost-effectiveness internet-delivered cognitive behaviour
 therapy (ICBT) for related disorders have found similar results. For example, (22)
 found that an internet-delivered CBT for obsessive-compulsive disorder produced

an additional remission for \$672 and one additional QALY for \$4800 compared to

288 online supportive therapy. In cost-effectiveness analyses of ICBT for health

anxiety, savings of £1244 per additional case of remission were found compared 290 to an attention control condition (23), and several forms of low-intensity treatments were found to be cost-effective compared to waiting list (£-134 to £416 292 per additional case in remission) (24). Similarly, ICBT for depression was associated with a cost of €1817 for each additional reliably improved participant 294 (25) and has been estimated to be cost-effective at a societal willingness to pay of £20 000 per additional QALY compared to usual care (26). Caution should be 296 taken in directly comparing results from different studies since they may differ in the estimation of costs, outcome definitions, health care context, or comparators. 298 Keeping this limitation in mind, a meta-analysis of ICBT for various conditions found that the treatments are cost-effective options by providing large clinical 300 gains at relatively low cost (27). The results should be viewed in light of several limitations. First, the current study 302 used self-reported costs from the TIC-P, which might not capture all costs associated with treatment. However, the cost estimations from the TIC-P are 304 reliable and correspond well to costs estimated from medical registrations (28). Second, BDD-NET was compared to supportive psychotherapy which is not an 306 established treatment for BDD, however face to face supportive psychotherapy was associated with comparable gains to CBT for BDD in a recent randomised 308 controlled trial, indicating that it is an effective treatment for some patients with BDD (3). Third, participants in this study were self-referred and thus likely to be 310 motivated to undergo treatment. This may not be representative for the whole population of patients with BDD, who may have poor insight and be less 312 motivated to seek help for their problems.

Future research should directly compare the efficacy and cost-effectiveness of 314 BDD-NET to face-to-face CBT for BDD, which together with SSRI medication, is a first line treatment for BDD. Additionally, evaluation of BDD-NET in regular psychiatric care is needed as these patients may differ in level of insight, 316 psychiatric comorbidity and willingness to undergo psychological treatment for 318 their BDD, compared to self-referred participants. In conclusion, BDD-NET is a cost-effective treatment for BDD, compared to 320 online supportive psychotherapy. The results have direct implications for rational decision-making in health care, where information on the cost-effectiveness of 322 treatment alternatives can improve the distribution of limited resources, thus providing effective treatment to more patients at a minimal cost.

324

Article information

326 Funding

This research received no specific grant from any funding agency in the public,

- 328 commercial or not-for-profit sectors. The original clinical trial was funded through the regional agreement on medical training and clinical research (ALF)
- between the Region Stockholm and Karolinska Institutet, the Swedish Research Council (no. K2013-61X-22168-01-3) and the Swedish Society of Medicine
- 332 (Söderströmska Königska sjukhemmet, no. SLS3B4451).

The funders had no part in the study design, in the collection, analysis and

interpretation of data, in the writing of the report or in the decision to submit the article for publication.

336 Ethical approval

The regional ethical review board in Stockholm approved the protocol

338 (registration ID: 2013/1773-31/4). All participants gave written informed consent.

Competing interests

340 None declared.

Contributors

- 342 JE and CR had the original idea for the study and, with DM-C, designed the trial variables and obtained funding. JE and CR were responsible for study
- supervision. OF carried out the statistical analysis and drafted the manuscript,

which was revised by EA, GG, DM-C, DD, CR and JE. All authors approved the

346 final version to be submitted.

Data sharing statement

- The datasets analysed are not publicly available since they contain sensitive personal identifying information and data sharing was not part of the written
- informed consent, but are available from the corresponding author on reasonable request. Statistical code is publicly available from the Open Science Framework
- 352 repository: https://doi.org/10.17605/OSF.IO/DC69E

References

- 354 1. Veale D, Anson M, Miles S, Pieta M, Costa A, Ellison N. Efficacy of Cognitive Behaviour Therapy versus Anxiety Management for Body Dysmorphic Disorder:
- A Randomised Controlled Trial. Psychotherapy and Psychosomatics. 2014 Jan;83(6):341–53.
- Wilhelm S, Phillips KA, Didie E, Buhlmann U, Greenberg JL, Fama JM, et al.
 Modular Cognitive-Behavioral Therapy for Body Dysmorphic Disorder: A
- Randomized Controlled Trial. Behavior Therapy. 2014 Jan;45(3):314–27.
 - 3. Wilhelm S, Phillips KA, Greenberg JL, O'Keefe SM, Hoeppner SS, Keshaviah
- A, et al. Efficacy and Posttreatment Effects of Therapist-Delivered Cognitive

 Behavioral Therapy vs Supportive Psychotherapy for Adults With Body
- 364 Dysmorphic Disorder: A Randomized Clinical Trial. JAMA psychiatry. 2019 Apr;76(4):363–73.

- 4. Harrison A, Fernández de la Cruz L, Enander J, Radua J, Mataix-Cols D.Cognitive-behavioral therapy for body dysmorphic disorder: A systematic review
- 368 and meta-analysis of randomized controlled trials. Clinical Psychology Review.
 2016 Aug;48:43–51.
- 5. Marques L, Weingarden HM, Leblanc NJ, Wilhelm S. Treatment utilization and barriers to treatment engagement among people with body dysmorphic
- 372 symptoms. Journal of Psychosomatic Research. 2011 Mar;70(3):286–93.
 - 6. Buhlmann U. Treatment barriers for individuals with body dysmorphic
- disorder: An internet survey. The Journal of Nervous and Mental Disease. 2011 Apr;199(4):268–71.
- 7. Shapiro DA, Cavanagh K, Lomas H. GEOGRAPHIC INEQUITY IN THE AVAILABILITY OF COGNITIVE BEHAVIOURAL THERAPY IN ENG
- 378 LAND AND WALES. Behavioural and Cognitive Psychotherapy. 2003 Apr;31(2):185–92.
- 380 8. Andersson G, Titov N, Dear BF, Rozental A, Carlbring P. Internet-delivered psychological treatments: From innovation to implementation. World Psychiatry.
- 382 2019 Feb;18(1):20–8.
 - 9. Enander J, Andersson E, Mataix-Cols D, Lichtenstein L, Alström K, Andersson
- 384 G, et al. Therapist guided internet based cognitive behavioural therapy for body dysmorphic disorder: Single blind randomised controlled trial. BMJ. 2016
- 386 Feb;352:i241.

- 10. Enander J, Ljótsson B, Anderhell L, Runeborg M, Flygare O, Cottman O, et
- al. Long-term outcome of therapist-guided internet-based cognitive behavioural therapy for body dysmorphic disorder (BDD-NET): A naturalistic 2-year follow-
- up after a randomised controlled trial. BMJ Open. 2019 Jan;9(1):e024307.
 - 11. Gentile AJ, La Lima C, Flygare O, Enander J, Wilhelm S, Mataix-Cols D, et
- 392 al. Internet-based, therapist-guided, cognitiveBehavioural therapy for body dysmorphic disorder with global eligibility for inclusion: An uncontrolled pilot
- 394 study. BMJ Open. 2019 Mar;9(3):e024693.
 - 12. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et
- 396 al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013 Mar;346:f1049.
- 398 13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Pub; 2013.
- 400 14. Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C,Goodman WK. A severity rating scale for body dysmorphic disorder:
- Development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacology Bulletin. 1997;33(1):17–22.
- 404 15. Enander J, Ivanov VZ, Andersson E, Mataix-Cols D, Ljótsson B, Rück C.
 Therapist-guided, Internet-based cognitiveBehavioural therapy for body
- 406 dysmorphic disorder (BDD-NET): A feasibility study. BMJ Open. 2014 Sep;4(9):e005923.

- 408 16. Rabin R, Charro F de. EQ-SD: A measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43.
- 410 17. Hakkaart-van Roijen L, Van Straten A, Donker M, Tiemens B, van Straten A, Roijen L, et al. Trimbos/iMTA questionnaire for costs associated with psychiatric
- 412 illness (TiC-P). 2002 Jan;
 - 18. Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van
- 414 Roijen L. Update of the Dutch manual for costing studies in health care. Prinja S, editor. PLOS ONE. 2017 Nov;12(11):e0187477.
- 416 19. Drummond MF, Stoddart GL, Torrance GW, Sculpher MJ, O'Brian BJ.Methods for the Economic Evaluation of Health Care Programmes. Third edition.
- 418 New York: Oxford University Press; 2005.
 - 20. Russell VL. Emmeans: Estimated Marginal Means, aka Least-Squares Means.
- 420 2020.
 - 21. R Core Team. R: A language and environment for statistical computing.
- 422 Vienna, Austria: R Foundation for Statistical Computing; 2020.
 - 22. Andersson E, Hedman E, Ljótsson B, Wikström M, Elveling E, Lindefors N,
- et al. Cost-effectiveness of internet-based cognitive behavior therapy for obsessive-compulsive disorder: Results from a randomized controlled trial.
- 426 Journal of Obsessive-Compulsive and Related Disorders. 2015 Jan;4:47–53.
 - 23. Hedman E, Andersson E, Lindefors N, Andersson G, Rück C, Ljótsson B.
- 428 Cost-effectiveness and long-term effectiveness of internet-based cognitive

- behaviour therapy for severe health anxiety. Psychological Medicine. 2013
- 430 Feb;43(2):363–74.
 - 24. Axelsson E, Andersson E, Ljótsson B, Hedman-Lagerlöf E. Cost-effectiveness
- and long-term follow-up of three forms of minimal-contact cognitive behaviour therapy for severe health anxiety: Results from a randomised controlled trial.
- 434 Behaviour Research and Therapy. 2018 Aug;107:95–105.
 - 25. Warmerdam L, Smit F, van Straten A, Riper H, Cuijpers P. Cost-utility and
- 436 cost-effectiveness of internet-based treatment for adults with depressive symptoms: Randomized trial. Journal of Medical Internet Research. 2010
- 438 Dec;12(5):e53.
 - 26. Hollinghurst S, Peters TJ, Kaur S, Wiles N, Lewis G, Kessler D. Cost-
- effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: Randomised controlled trial. The British Journal of Psychiatry: The
- 442 Journal of Mental Science. 2010 Oct;197(4):297–304.
 - 27. Donker T, Blankers M, Hedman E, Ljótsson B, Petrie K, Christensen H.
- Economic evaluations of Internet interventions for mental health: A systematic review. Psychological Medicine. 2015 Dec;45(16):3357–76.
- 28. Bouwmans C, De Jong K, Timman R, Zijlstra-Vlasveld M, Van der Feltz-Cornelis C, Tan Swan S, et al. Feasibility, reliability and validity of a
- questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). BMC health services research. 2013 Jun;13:217.

